(Q24245606)

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

Evaluation of a new highly purified pertussis vaccine in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

Acellular pertussis vaccines developed in Japan and their application for disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

A search for Bordetella pertussis infection in university students

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

Pertussis in Sweden after the cessation of general immunization in 1979.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

Acellular pertussis vaccines: the rationale for an efficacy trial in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Bias in the one-step method for pooling study results.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Protective effect of acellular pertussis vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 micrograms of FHA and either 25 or 8 micrograms of PT with response to whole-cell pertussis DTP vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Comparison of acellular (B type) and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15- to 24-month-old children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Development of a pertussis component vaccine in Japan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Language bias in randomised controlled trials published in English and German.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Bias in treatment assignment in controlled clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

A placebo-controlled trial of a pertussis-toxoid vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Pertussis immunization with acellular vaccines in Ghanaian children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Pertussis in German adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

The multicenter acellular pertussis trial: an overview

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Efficacy and safety of acellular pertussis vaccine in Aichi Prefecture, Japan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Comparison of a three-component acellular pertussis vaccine with whole cell pertussis vaccine in two-month-old children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Metabolic and hematologic effects and immune complex formation related to pertussis immunization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021

Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB2

7 January 2021